Last Update 24 Oct 25
Fair value Decreased 2.89%Analysts have lowered their price target for Align Technology by approximately $5 to $175. They cite slightly softer revenue growth projections, modestly reduced profit margin expectations, and increased uncertainty around guidance for the upcoming quarters.
Analyst Commentary
Analysts have recently provided updated perspectives on Align Technology, reflecting both optimistic and cautious viewpoints as the company approaches upcoming earnings reports.
Bullish Takeaways- Bullish analysts remain confident in the company's long-term growth prospects. They maintain positive ratings despite lowering price targets.
- Recent model updates suggest results are still expected to be in line with consensus expectations, which offers reassurance to investors.
- Some analysts see current share price weakness as a buying opportunity, particularly if shares decline sharply following results.
- There is a continued belief that Align Technology's core business fundamentals remain strong. This supports potential for future recovery in valuation.
- Cautious analysts have trimmed price targets, citing reduced confidence in the company's ability to provide visibility on sequential improvement for upcoming quarters.
- Smaller profit margin expectations have contributed to a more conservative outlook on near-term performance.
- There is increased uncertainty around guidance. This has led to skepticism about Align Technology's execution and pace of recovery in the short term.
What's in the News
- Align Technology showcased new digital orthodontic innovations and clinical workflows at the 2025 Invisalign GP Summit, emphasizing peer-led education and patient experience. (Key Developments)
- The company issued guidance for Q3 and full-year 2025, projecting Q3 revenues of $965 to $985 million, with full-year clear aligner volume growth expected in the low-single digits and overall revenue growth flat to slightly up from 2024, assuming current foreign exchange rates. (Key Developments)
- No shares were repurchased by Align Technology from April 1 to June 30, 2025, as part of their previously announced buyback program. (Key Developments)
Valuation Changes
- Consensus Analyst Price Target has decreased modestly, moving from $180.29 previously to $175.07.
- Discount Rate has risen slightly, from 7.40% to 7.47%.
- Revenue Growth expectations have been adjusted downward, now projected at 4.58% compared to the prior 4.64%.
- Net Profit Margin forecast has declined marginally, shifting from 14.85% to 14.81%.
- Future P/E Ratio is now estimated at 21.35x, down from 21.85x before.
Key Takeaways
- Expansion into new clinical segments and broader international adoption are set to significantly boost long-term revenue and earnings growth.
- Investments in digital technology, automation, and targeted consumer strategies will enhance operational efficiency, margins, and competitive differentiation.
- Macroeconomic challenges, shifting treatment preferences, lower-priced product mix, constrained equipment demand, and heightened competition are pressuring margins and limiting Align's revenue and earnings growth.
Catalysts
About Align Technology- Designs, manufactures, and markets Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services in the United States, Switzerland, and internationally.
- Demand for Invisalign remains robust across international markets-especially in APAC, EMEA, and Latin America-where rising incomes and a growing middle class are increasing access to discretionary dental procedures; as consumer confidence returns, this pent-up global demand is likely to accelerate revenue growth.
- The continued expansion of clinical indications for Invisalign (such as Invisalign First for teens/kids and palate expanders) and the increasing adoption by general practitioner dentists are broadening Align's addressable market, positioning the company for higher long-term revenues and double-digit earnings growth as these new segments mature.
- Strategic investments in digital workflow and next-generation manufacturing (automation, regionalized production, modernization of facilities) are expected to drive operational efficiencies and cost reductions, supporting higher net margins and improved operating leverage in fiscal 2026 and beyond.
- The integration of advanced digital solutions-such as iTero Lumina scanners, AI-driven treatment planning, and piloting x-ray diagnostics integration-will enhance differentiation, support premium pricing, and improve patient treatment outcomes, ultimately benefiting both revenues and long-term earnings quality.
- Align's commitment to direct-to-consumer engagement and targeted marketing programs (especially in digital channels and emerging direct provider relationships like DSOs) is poised to accelerate patient conversion rates and expand global adoption, driving sustained revenue and earnings growth as market conditions stabilize.
Align Technology Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?- Analysts are assuming Align Technology's revenue will grow by 4.6% annually over the next 3 years.
- Analysts assume that profit margins will increase from 11.0% today to 14.9% in 3 years time.
- Analysts expect earnings to reach $674.8 million (and earnings per share of $9.55) by about September 2028, up from $437.6 million today.
- In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 22.6x on those 2028 earnings, up from 22.5x today. This future PE is lower than the current PE for the US Medical Equipment industry at 29.7x.
- Analysts expect the number of shares outstanding to decline by 2.9% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.42%, as per the Simply Wall St company report.
Align Technology Future Earnings Per Share Growth
Risks
What could happen that would invalidate this narrative?- Persistent macroeconomic uncertainty-including global tariff volatility, inflation, high interest rates, and weak consumer confidence-is contributing to reduced patient traffic, fewer orthodontic case starts, and lower acceptance rates for elective clear aligner treatments, challenging Align's future revenue growth.
- A multi-year trend of declining orthodontic case starts in developed markets and a notable shift by orthodontists towards traditional metal braces (wires and brackets) in times of uncertainty indicate secular demand headwinds, which may pressure aligner volumes and revenues in the long term.
- Product mix is moving towards lower-priced, noncomprehensive aligner products and increased sales in emerging markets where product pricing is structurally lower, driving down clear aligner average selling prices (ASPs) and putting downward pressure on net margins and total earnings.
- Reluctance among dental practices to invest in new capital equipment due to weaker patient traffic and subdued demand is constraining sales of higher-margin scanner systems and shifting revenues toward less profitable upgrade parts, limiting potential margin expansion.
- Intensifying pricing discounting, continued competitive pressure from both traditional braces and regional clear aligner competitors, and increased restructuring/cost-saving initiatives signal a challenging operating environment, raising the risk of compressed operating margins and lower sustainable earnings, especially if top-line growth remains muted.
Valuation
How have all the factors above been brought together to estimate a fair value?- The analysts have a consensus price target of $186.357 for Align Technology based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $220.0, and the most bearish reporting a price target of just $140.0.
- In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $4.5 billion, earnings will come to $674.8 million, and it would be trading on a PE ratio of 22.6x, assuming you use a discount rate of 7.4%.
- Given the current share price of $135.93, the analyst price target of $186.36 is 27.1% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
How well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.



